Related Experiment Video

Updated: Apr 17, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.4K

Hypertrophic cardiomyopathy: a review

Brian A Houston1, Gerin R Stevens1

  • 1Division of Cardiology, Department of Medicine, Johns Hopkins Hospital, Baltimore, MD, USA.

Clinical Medicine Insights. Cardiology
|February 7, 2015
PubMed

Insights

Hypertrophic cardiomyopathy (HCM) is a genetic heart disease affecting diverse populations globally. This review focuses on managing HCM patients, particularly those experiencing heart failure symptoms.

Area of Science:

  • Cardiology
  • Genetics
  • Heart Failure

Background:

  • Hypertrophic cardiomyopathy (HCM) is a prevalent global genetic heart condition.
  • It affects diverse populations across all continents, genders, and ethnicities.
  • HCM is primarily a monogenic disorder linked to sarcomeric gene mutations.

Purpose of the Study:

  • To review the current approach to managing patients with hypertrophic cardiomyopathy (HCM).
  • To specifically address the clinical management of HCM patients presenting with heart failure.
  • To highlight recent advancements in understanding and treating HCM and heart failure.

Main Methods:

  • Literature review of recent advancements in HCM and heart failure management.
  • Synthesis of current clinical guidelines and research findings.
  • Focus on diagnostic and therapeutic strategies for HCM with heart failure.

Main Results:

  • HCM presents a spectrum of clinical manifestations, from sudden cardiac death to heart failure symptoms.
  • Effective management requires a comprehensive understanding of HCM's genetic basis and clinical course.
  • Recent progress offers new insights into treating HCM, especially when heart failure is present.

Conclusions:

  • A multidisciplinary approach is crucial for managing HCM patients with heart failure.
  • Ongoing research continues to refine treatment strategies for hypertrophic cardiomyopathy.
  • Early diagnosis and tailored interventions improve outcomes for HCM patients, particularly those with heart failure.

Keywords:
LV hypertrophyheart failurehypertrophic cardiomyopathy

More Related Videos

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level06:02

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

Published on: November 2, 2020

6.3K
Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

10.8K

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
801
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
721
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
869
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
805
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
920
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.5K